Q3 2024 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2024-11-14 · accession 0000950123-24-011486
$160.0M
Reported value
11
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 055477103 | BCAX | Bicara Therapeutics Inc. | $56.2M | 35.1% | 2,204,650 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio | $29.9M | 18.7% | 13,072,340 | Common | SOLE |
| 76029N106 | REPL | Replimune Group | $27.0M | 16.9% | 2,461,319 | Common | SOLE |
| 52886X107 | LXEO | Lexeo Therapeutics | $21.3M | 13.3% | 2,355,904 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $7.1M | 4.44% | 1,076,357 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc | $7.0M | 4.36% | 653,223 | Common | SOLE |
| 45175G108 | — | Ikena Oncology | $3.9M | 2.43% | 2,249,123 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $3.5M | 2.19% | 843,750 | Common | SOLE |
| 4525EP101 | VTLUSD | Immunic Inc | $3.0M | 1.84% | 1,788,160 | Common | SOLE |
| 29286M113 | — | enGene Holdings Inc. | $675,154 | 0.42% | 321,502 | Common | SOLE |
| 87184Q206 | SYRS | Syros Pharmaceuticals | $540,231 | 0.34% | 251,270 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.